Skip to main content

Table 1 Demographics and indications for treatment

From: Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia

  Thalidomide (N = 67) Bevacizumab (N = 69)
N % N %
Gender (% male) 41 61.2 23 33.3
Pathogenic gene
ENG (HHT1) 17 25.4 10 14.5
ACVRL1 (HHT2) 34 50.7 57 82.6
SMAD4 (JPHT) 2 3.0 1 1.4
 Not known 14 20.9 1 1.4
Treatment indication
 Epistaxis 48 71.6 14 20.3
 GI bleeding 11 16.4 8 11.6
 Epistaxis and GI bleeding 8 11.9 10 14.5
 High output cardiac failure 0 0 37 53.6
  1. Legend: N number of cases treated, GI gastrointestinal